CN115297872A - 含有线粒体的组合物及其修复软骨损伤或改善退化性关节炎的用途 - Google Patents

含有线粒体的组合物及其修复软骨损伤或改善退化性关节炎的用途 Download PDF

Info

Publication number
CN115297872A
CN115297872A CN202180022422.7A CN202180022422A CN115297872A CN 115297872 A CN115297872 A CN 115297872A CN 202180022422 A CN202180022422 A CN 202180022422A CN 115297872 A CN115297872 A CN 115297872A
Authority
CN
China
Prior art keywords
mitochondria
composition
cells
degenerative arthritis
cartilage damage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202180022422.7A
Other languages
English (en)
Other versions
CN115297872B (zh
Inventor
郑汉中
许智凯
杨舜杰
郑安玲
凃启堂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Chung Hsing University
Original Assignee
National Chung Hsing University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Chung Hsing University filed Critical National Chung Hsing University
Priority to CN202410414725.9A priority Critical patent/CN118236473A/zh
Priority to CN202410414731.4A priority patent/CN118252850A/zh
Publication of CN115297872A publication Critical patent/CN115297872A/zh
Application granted granted Critical
Publication of CN115297872B publication Critical patent/CN115297872B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/02—Blood transfusion apparatus
    • A61M1/029—Separating blood components present in distinct layers in a container, not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3693—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits using separation based on different densities of components, e.g. centrifuging
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/80—Undefined extracts from animals
    • C12N2500/84—Undefined extracts from animals from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/998—Proteins not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/115—Platelets, megakaryocytes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Anesthesiology (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)

Abstract

本发明一个实施例提供包含线粒体的组合物，藉由对软骨提供线粒体，可通过改善软骨细胞中线粒体的功能以提升软骨细胞的修复能力并修复软骨细胞老化导致的软骨损伤，进而达到改善并治疗退化性关节炎的目的。

Description

PCT国内申请，说明书已公开。

Claims (13)

  1. PCT国内申请，权利要求书已公开。
CN202180022422.7A 2020-03-20 2021-03-22 含有线粒体的组合物及其修复软骨损伤或改善退化性关节炎的用途 Active CN115297872B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202410414725.9A CN118236473A (zh) 2020-03-20 2021-03-22 用于修复软骨损伤或改善退化性关节炎的含有线粒体的组合物
CN202410414731.4A CN118252850A (zh) 2020-03-20 2021-03-22 含有线粒体的组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062992546P 2020-03-20 2020-03-20
US62/992,546 2020-03-20
PCT/CN2021/082094 WO2021185376A1 (zh) 2020-03-20 2021-03-22 含有线粒体的组合物及其修复软骨损伤或改善退化性关节炎的用途

Related Child Applications (2)

Application Number Title Priority Date Filing Date
CN202410414725.9A Division CN118236473A (zh) 2020-03-20 2021-03-22 用于修复软骨损伤或改善退化性关节炎的含有线粒体的组合物
CN202410414731.4A Division CN118252850A (zh) 2020-03-20 2021-03-22 含有线粒体的组合物

Publications (2)

Publication Number Publication Date
CN115297872A true CN115297872A (zh) 2022-11-04
CN115297872B CN115297872B (zh) 2024-03-29

Family

ID=77768010

Family Applications (12)

Application Number Title Priority Date Filing Date
CN202410329264.5A Pending CN118319951A (zh) 2020-03-20 2021-03-19 修复肌腱损伤的组合物
CN202311570784.7A Pending CN117357559A (zh) 2020-03-20 2021-03-19 线粒体萃取物用于治疗或/及预防肾脏损伤相关疾病的用途
CN202410329249.0A Pending CN118319950A (zh) 2020-03-20 2021-03-19 线粒体用于治疗关节疾病或韧带损伤相关疾病的用途
CN202180022924.XA Pending CN115335065A (zh) 2020-03-20 2021-03-19 细胞培养组合物及其用途
CN202180014788.XA Active CN115315265B (zh) 2020-03-20 2021-03-19 线粒体用于促进伤口修复及/或伤口愈合的用途
CN202180014777.1A Active CN115103683B (zh) 2020-03-20 2021-03-19 线粒体用于治疗及/或预防肌腱受损或其相关疾病的用途
CN202180014670.7A Active CN115135328B (zh) 2020-03-20 2021-03-19 线粒体萃取物用于治疗或/及预防肾脏损伤相关疾病的用途
CN202311621466.9A Pending CN117379458A (zh) 2020-03-20 2021-03-19 线粒体萃取物用于治疗或/及预防肾脏损伤相关疾病的用途
CN202180022422.7A Active CN115297872B (zh) 2020-03-20 2021-03-22 含有线粒体的组合物及其修复软骨损伤或改善退化性关节炎的用途
CN202410414731.4A Pending CN118252850A (zh) 2020-03-20 2021-03-22 含有线粒体的组合物
CN202180022370.3A Pending CN115315248A (zh) 2020-03-20 2021-03-22 促进毛发再生的组合物、富线粒体血浆、其制造方法及其用途
CN202410414725.9A Pending CN118236473A (zh) 2020-03-20 2021-03-22 用于修复软骨损伤或改善退化性关节炎的含有线粒体的组合物

Family Applications Before (8)

Application Number Title Priority Date Filing Date
CN202410329264.5A Pending CN118319951A (zh) 2020-03-20 2021-03-19 修复肌腱损伤的组合物
CN202311570784.7A Pending CN117357559A (zh) 2020-03-20 2021-03-19 线粒体萃取物用于治疗或/及预防肾脏损伤相关疾病的用途
CN202410329249.0A Pending CN118319950A (zh) 2020-03-20 2021-03-19 线粒体用于治疗关节疾病或韧带损伤相关疾病的用途
CN202180022924.XA Pending CN115335065A (zh) 2020-03-20 2021-03-19 细胞培养组合物及其用途
CN202180014788.XA Active CN115315265B (zh) 2020-03-20 2021-03-19 线粒体用于促进伤口修复及/或伤口愈合的用途
CN202180014777.1A Active CN115103683B (zh) 2020-03-20 2021-03-19 线粒体用于治疗及/或预防肌腱受损或其相关疾病的用途
CN202180014670.7A Active CN115135328B (zh) 2020-03-20 2021-03-19 线粒体萃取物用于治疗或/及预防肾脏损伤相关疾病的用途
CN202311621466.9A Pending CN117379458A (zh) 2020-03-20 2021-03-19 线粒体萃取物用于治疗或/及预防肾脏损伤相关疾病的用途

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN202410414731.4A Pending CN118252850A (zh) 2020-03-20 2021-03-22 含有线粒体的组合物
CN202180022370.3A Pending CN115315248A (zh) 2020-03-20 2021-03-22 促进毛发再生的组合物、富线粒体血浆、其制造方法及其用途
CN202410414725.9A Pending CN118236473A (zh) 2020-03-20 2021-03-22 用于修复软骨损伤或改善退化性关节炎的含有线粒体的组合物

Country Status (6)

Country Link
US (6) US20230137870A1 (zh)
EP (2) EP4122474A4 (zh)
JP (1) JP2023518083A (zh)
CN (12) CN118319951A (zh)
TW (8) TW202404618A (zh)
WO (6) WO2021185341A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116478920A (zh) * 2023-05-05 2023-07-25 重庆理工大学 一种离体线粒体的体外储存方法

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070021496A1 (en) * 1999-09-15 2007-01-25 Migenix Corp. Methods and compositions for diagnosing and treating arthritic disorders and regulating bone mass
CN1914336A (zh) * 2004-02-02 2007-02-14 雀巢技术公司 犬骨关节炎相关基因及相关的方法和组合物
WO2013035101A1 (en) * 2011-09-11 2013-03-14 Minovia Therapeutics Ltd. Compositions of functional mitochondria and uses thereof
CN104546915A (zh) * 2015-02-16 2015-04-29 黑龙江天晴干细胞股份有限公司 一种治疗骨性关节炎的组合物、其制备方法及其应用
CN105520891A (zh) * 2014-09-30 2016-04-27 李德财 以外源性线粒体为有效成份的组合物、其用途及修复细胞的方法
CN106822183A (zh) * 2016-12-26 2017-06-13 上海斯能得医疗科技有限公司 一种光敏富血小板血浆凝胶及其制备方法和用途
US20170224764A1 (en) * 2016-02-10 2017-08-10 Cornell University Therapeutic targeting of mitochondria to prevent osteoarthritis
CN110022884A (zh) * 2016-11-30 2019-07-16 白雁生物技术公司 含有线粒体的药物组合物
CN110055216A (zh) * 2019-05-09 2019-07-26 张秀明 一种改善间质干细胞生物学功能的方法
WO2019151840A1 (ko) * 2018-02-02 2019-08-08 주식회사 파이안바이오테크놀로지 분리된 미토콘드리아를 포함하는 류마티스 관절염 예방 또는 치료용 약학 조성물
CN110812480A (zh) * 2019-11-28 2020-02-21 中国科学院昆明动物研究所 一种抗菌肽和线粒体dna复合物及其多克隆抗体和应用
US20200171215A1 (en) * 2017-06-01 2020-06-04 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Formation of stable cartilage
CN112154210A (zh) * 2018-03-13 2020-12-29 利兰斯坦福初级大学董事会 用于逆转细胞老化的瞬时细胞重编程

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009002811A2 (en) * 2007-06-22 2008-12-31 Children's Medical Center Corporation Therapeutic platelet compositions and methods
US8734854B2 (en) * 2009-07-09 2014-05-27 Orogen Biosciences Inc. Process for removing growth factors from platelets
US20130022666A1 (en) * 2011-07-20 2013-01-24 Anna Brzezinska Methods and compositions for transfer of mitochondria into mammalian cells
EP2591812A1 (en) * 2011-11-14 2013-05-15 University of Twente, Institute for Biomedical Technology and Technical Medicine (MIRA) A dextran-based tissuelette containing platelet-rich plasma lysate for cartilage repair
US20140024677A1 (en) * 2012-04-09 2014-01-23 Musc Foundation For Research Development Methods for inducing mitochondrial biogenesis
US10702556B2 (en) * 2012-05-16 2020-07-07 Minovia Therpautices Ltd. Compositions and methods for inducing angiogenesis
WO2014121481A1 (zh) * 2013-02-07 2014-08-14 李震义 长效人重组可溶性肿瘤坏死因子α受体在制备预防和治疗慢性肝病重症肝损伤药物中的用途
US20150064715A1 (en) * 2013-08-28 2015-03-05 Musc Foundation For Research Development Urinary biomarkers of renal and mitochondrial dysfunction
TW201509425A (zh) * 2013-09-13 2015-03-16 Taichung Hospital Ministry Of Health And Welfare 以血液製備修復傷口用醫藥組合物之方法
TWI672147B (zh) * 2014-09-10 2019-09-21 台灣粒線體應用技術股份有限公司 以外源性粒線體爲有效成份之組合物、其用途及修復細胞之方法
WO2016106660A1 (zh) * 2014-12-31 2016-07-07 国立中兴大学 新颖医药组合物及其用于治疗肺损伤的用途
BR112017015004A2 (pt) * 2015-01-15 2018-01-23 K Boss William Jr reparação e rejuvenescimento de tecidos usando plasma rico em plaquetas.
JP7015169B2 (ja) * 2015-02-26 2022-02-02 ミノヴィア セラピューティクス リミテッド 機能性ミトコンドリアで富化された哺乳動物細胞
CN105030647B (zh) * 2015-09-14 2018-04-24 广州赛莱拉干细胞科技股份有限公司 一种减少皱纹的制剂及其制备方法
JP2018535749A (ja) * 2015-11-02 2018-12-06 ベリグラフト アーベー 創傷を治癒するための組成物および方法
CN105477018A (zh) * 2015-12-07 2016-04-13 深圳爱生再生医学科技有限公司 修复皮肤溃疡的干细胞制剂及其制备方法
CN109152795A (zh) * 2016-01-15 2019-01-04 儿童医学中心公司 线粒体和组合的线粒体试剂的治疗用途
TWI637748B (zh) * 2016-07-12 2018-10-11 中山醫學大學 蓮蓬萃取物用於治療及／或預防腎臟病變之用途
CN106190963A (zh) * 2016-07-13 2016-12-07 浙江大学 一种采用线粒体移植促进损伤神经元存活的方法
WO2018178970A1 (en) * 2017-03-26 2018-10-04 Minovia Therapeutics Ltd. Mitochondrial compositions and methods for treatment of skin and hair
EP3624830A4 (en) * 2017-05-15 2020-12-30 Miron, Richard J. LIQUID LABEL-RICH FIBRIN AS A CARRIER SYSTEM FOR BIOMATERIALS AND BIOMOLECULES
US20190008896A1 (en) * 2017-07-07 2019-01-10 Richard Postrel Methods and Systems for the Prevention, Treatment and Management of Disease and Effects of Aging Via Cell-to-Cell Restoration Therapy Using Subcellular Transactions
CN107625969A (zh) * 2017-10-18 2018-01-26 南京市儿童医院 MiR‑214拮抗剂在制备用于减轻蛋白尿引起的肾小管损伤相关病症的药物中的用途
WO2019083201A2 (ko) * 2017-10-24 2019-05-02 주식회사 엑소코바이오 지방줄기세포 유래의 엑소좀을 유효성분으로 포함하는 조성물의 신장 기능 개선 용도
KR20190052266A (ko) * 2017-11-08 2019-05-16 원광대학교산학협력단 우르솔산을 유효성분으로 포함하는 신장 기능의 개선 또는 치료용 조성물
WO2019183042A1 (en) * 2018-03-20 2019-09-26 Unity Biotechnology, Inc. Autologous mitochondrial extraction and expansion
US20210275587A1 (en) * 2018-07-22 2021-09-09 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy of renal diseases
AU2019311862A1 (en) * 2018-07-22 2021-02-04 Minovia Therapeutics Ltd. Mitochondrial augmentation therapy with stem cells enriched with functional mitochondria
WO2020054829A1 (ja) * 2018-09-14 2020-03-19 ルカ・サイエンス株式会社 ミトコンドリアのリンパ器官への移植およびそのための組成物
WO2020091463A1 (ko) * 2018-10-31 2020-05-07 차의과학대학교 산학협력단 분리된 미토콘드리아를 포함하는 건병증 예방 또는 치료용 약학 조성물
CN110638833A (zh) * 2019-11-15 2020-01-03 西安圣德生物科技有限公司 促进毛发生长的组合物及其使用方法

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070021496A1 (en) * 1999-09-15 2007-01-25 Migenix Corp. Methods and compositions for diagnosing and treating arthritic disorders and regulating bone mass
CN1914336A (zh) * 2004-02-02 2007-02-14 雀巢技术公司 犬骨关节炎相关基因及相关的方法和组合物
WO2013035101A1 (en) * 2011-09-11 2013-03-14 Minovia Therapeutics Ltd. Compositions of functional mitochondria and uses thereof
CN105520891A (zh) * 2014-09-30 2016-04-27 李德财 以外源性线粒体为有效成份的组合物、其用途及修复细胞的方法
CN104546915A (zh) * 2015-02-16 2015-04-29 黑龙江天晴干细胞股份有限公司 一种治疗骨性关节炎的组合物、其制备方法及其应用
US20170224764A1 (en) * 2016-02-10 2017-08-10 Cornell University Therapeutic targeting of mitochondria to prevent osteoarthritis
CN110022884A (zh) * 2016-11-30 2019-07-16 白雁生物技术公司 含有线粒体的药物组合物
CN106822183A (zh) * 2016-12-26 2017-06-13 上海斯能得医疗科技有限公司 一种光敏富血小板血浆凝胶及其制备方法和用途
US20200171215A1 (en) * 2017-06-01 2020-06-04 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Formation of stable cartilage
WO2019151840A1 (ko) * 2018-02-02 2019-08-08 주식회사 파이안바이오테크놀로지 분리된 미토콘드리아를 포함하는 류마티스 관절염 예방 또는 치료용 약학 조성물
CN112154210A (zh) * 2018-03-13 2020-12-29 利兰斯坦福初级大学董事会 用于逆转细胞老化的瞬时细胞重编程
CN110055216A (zh) * 2019-05-09 2019-07-26 张秀明 一种改善间质干细胞生物学功能的方法
CN110812480A (zh) * 2019-11-28 2020-02-21 中国科学院昆明动物研究所 一种抗菌肽和线粒体dna复合物及其多克隆抗体和应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BLANCO FJ等: "The role of mitochondria in osteoarthritis", vol. 7, no. 3, pages 161 - 169, XP055851733, DOI: 10.1038/nrrheum.2010.213 *
TANG Q等: "Trehalose ameliorates oxidative stress-mediated mitochondrial dysfunction and ER stress via selective autophagy stimulation and autophagic flux restoration in osteoarthritis development.", vol. 8, no. 10, pages 1 - 14 *
周明等: "自体去白细胞富血小板血浆治疗膝骨关节炎的早期临床疗效观察" *
周明等: "自体去白细胞富血小板血浆治疗膝骨关节炎的早期临床疗效观察", 《解放军医学院学报》, vol. 40, no. 8, pages 757 - 763 *

Also Published As

Publication number Publication date
EP4122474A4 (en) 2024-05-01
US20230016499A1 (en) 2023-01-19
CN118252850A (zh) 2024-06-28
CN115335065A (zh) 2022-11-11
WO2021185377A1 (zh) 2021-09-23
US20230023438A1 (en) 2023-01-26
CN115297872B (zh) 2024-03-29
CN115103683A (zh) 2022-09-23
TWI789724B (zh) 2023-01-11
CN115135328B (zh) 2024-01-02
EP4122474A1 (en) 2023-01-25
CN118236473A (zh) 2024-06-25
US20230137870A1 (en) 2023-05-04
TW202308668A (zh) 2023-03-01
TW202135837A (zh) 2021-10-01
TW202135838A (zh) 2021-10-01
CN115315265B (zh) 2024-05-31
US20230042445A1 (en) 2023-02-09
TWI787763B (zh) 2022-12-21
WO2021185364A1 (zh) 2021-09-23
EP4122444A1 (en) 2023-01-25
TW202135839A (zh) 2021-10-01
TW202135836A (zh) 2021-10-01
CN115103683B (zh) 2024-04-09
TWI787761B (zh) 2022-12-21
CN118319950A (zh) 2024-07-12
CN118319951A (zh) 2024-07-12
TW202135779A (zh) 2021-10-01
TWI789723B (zh) 2023-01-11
US20230023218A1 (en) 2023-01-26
TWI796653B (zh) 2023-03-21
CN117357559A (zh) 2024-01-09
WO2021185342A1 (zh) 2021-09-23
JP2023518083A (ja) 2023-04-27
CN115315265A (zh) 2022-11-08
TW202200781A (zh) 2022-01-01
TWI827321B (zh) 2023-12-21
TW202404618A (zh) 2024-02-01
US20230165899A1 (en) 2023-06-01
WO2021185376A1 (zh) 2021-09-23
CN115135328A (zh) 2022-09-30
WO2021185340A1 (zh) 2021-09-23
TW202306576A (zh) 2023-02-16
CN115315248A (zh) 2022-11-08
EP4122444A4 (en) 2024-04-17
CN117379458A (zh) 2024-01-12
WO2021185341A1 (zh) 2021-09-23

Similar Documents

Publication Publication Date Title
Zhang et al. Bone marrow mesenchymal stem cell-derived exosomes prevent osteoarthritis by regulating synovial macrophage polarization
Čamernik et al. Mesenchymal stem cells in the musculoskeletal system: from animal models to human tissue regeneration?
Carr II et al. The role of biologic agents in the management of common shoulder pathologies: current state and future directions
US20210260129A1 (en) Cell Expansion Methods and Therapeutic Compositions
Yea et al. Regeneration of a full-thickness defect of rotator cuff tendon with freshly thawed umbilical cord-derived mesenchymal stem cells in a rat model
Rosochowicz et al. Conditioned medium–is it an undervalued lab waste with the potential for osteoarthritis management?
Chan et al. Safety study of allogeneic mesenchymal stem cell therapy in animal model
Linon et al. Engraftment of autologous bone marrow cells into the injured cranial cruciate ligament in dogs
CN115297872A (zh) 含有线粒体的组合物及其修复软骨损伤或改善退化性关节炎的用途
CN116474000B (zh) 脐带间充质干细胞制剂、制备方法及其在治疗膝骨关节炎中的应用
WO2007034521A1 (en) Use of bone marrow stromal cells for the treatment of tendons and/or ligaments damages
Shehata et al. Effect of mesenchymal stem cells on induced skeletal muscle chemodenervation atrophy in adult male albino rats
CN106110302A (zh) 治疗糖尿病足的干细胞制剂
JP2009040692A (ja) ヒト末梢血由来ｃｄ１３３／ｃｄ３４陽性細胞移植による筋損傷の修復
Wang et al. Effects of transplanted GDNF gene modified marrow stromal cells on focal cerebral ischemia in rats
Castillo-Franz et al. Evaluation of the Catabolic and Anabolic Gene Expression Effects and Histology Changes induced by Platelet-Rich Gel Supernatants in Equine Suspensory Ligament Explants Challenged with Lipopolysaccharide.
US20240174980A1 (en) Process for manufacture of a composition for the treatment of osteoarthritis in a subject
Fei et al. Hydrogen Enhanced the Myogenic Differentiation of Adipose Mesenchymal Stem Cells through P38 MAPK Signaling Pathway
CN117904037A (zh) 一种高效治疗骨关节炎的脂肪干细胞及其分离方法
Kim et al. Hemovac blood after total knee arthroplasty as a source of stem cells
Song et al. Effect of hypoxic paracrine media on calcium-regulatory proteins in infarcted rat myocardium
Nicpoń et al. AUTOLOGOUS STEM CELLS THERAPY IN HORSES AND DOGS WITH CHRONIC OSTEOARTHRITIS.
CN118165927A (zh) 一种人脐带间充质干细胞制剂、制备方法及其在治疗膝骨关节炎中的应用
WO2021225432A1 (en) Novel pharmaceutical composition and use thereof for repairing damaged liver, treating disease associated with damaged liver and improving functions of liver
CN117915925A (zh) 用于在动物中治疗骨关节炎的间充质干细胞

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant